Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis.
Because protein variants play critical roles in many diseases including TDP-43 in Amyotrophic Lateral Sclerosis (ALS), alpha-synuclein in Parkinson's disease and beta-amyloid and tau in Alzheimer's disease, it is critically important to develop morphology specific reagents that can selectively target these disease-specific protein variants to study the role of these variants in disease pathology and for potential diagnostic and therapeutic applications. We have developed novel atomic force microscopy (AFM) based biopanning techniques that enable isolation of reagents that selectively recognize disease-specific protein variants. There are two key phases involved in the process, the negative and positive panning phases. During the negative panning phase, phages that are reactive to off-target antigens are eliminated through multiple rounds of subtractive panning utilizing a series of carefully selected off-target antigens. A key feature in the negative panning phase is utilizing AFM imaging to monitor the process and confirm that all undesired phage particles are removed. For the positive panning phase, the target antigen of interest is fixed on a mica surface and bound phages are eluted and screened to identify phages that selectively bind the target antigen. The target protein variant does not need to be purified providing the appropriate negative panning controls have been used. Even target protein variants that are only present at very low concentrations in complex biological material can be utilized in the positive panning step. Through application of this technology, we acquired antibodies to protein variants of TDP-43 that are selectively found in human ALS brain tissue. We expect that this protocol should be applicable to generating reagents that selectively bind protein variants present in a wide variety of different biological processes and diseases.
School for Engineering of Matter, Transport and Energy, Arizona State University.
Stephanie M
SM
Williams
School for Engineering of Matter, Transport and Energy, Arizona State University.
Lalitha
L
Venkataraman
School for Engineering of Matter, Transport and Energy, Arizona State University.
Huilai
H
Tian
Department of Neurology, Georgetown University Medical Center.
Galam
G
Khan
Department of Neurology, Georgetown University Medical Center; Department of Pathology, Georgetown University Medical Center.
Brent T
BT
Harris
School for Engineering of Matter, Transport and Energy, Arizona State University; sierks@asu.edu.
Michael R
MR
Sierks
D000690:Amyotrophic Lateral Sclerosis / Q000276:immunology* / Q000378:metabolism; D000906:Antibodies / Q000737:chemistry* / Q000276:immunology* / Q000302:isolation & purification; D000918:Antibody Specificity; D000941:Antigens / Q000276:immunology; D001923:Brain Chemistry; D004268:DNA-Binding Proteins / Q000276:immunology* / Q000302:isolation & purification* / Q000378:metabolism; D006801:Humans; D018625:Microscopy, Atomic Force / Q000379:methods
D000906:Antibodies; D000941:Antigens; D004268:DNA-Binding Proteins; C000598624:TARDBP protein, human